News Laboratorios Farmaceuticos Rovi, S.A.

Equities

ROVI

ES0157261019

Market Closed - BME Other stock markets 11:35:19 2024-04-24 am EDT			5-day change	1st Jan Change
79.6 ^EUR	-1.06%		-2.51%	+32.23%

Apr. 02	Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment	MT
Mar. 12	Rovi, Partners to Form Entity for Advanced Therapies R&D	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment	Apr. 02	MT
Rovi, Partners to Form Entity for Advanced Therapies R&D	Mar. 12	MT
Laboratorios Farmaceuticos Rovi S A : ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies	Mar. 12	PU
Rovi explores sale of unit that makes drugs for third parties	Mar. 07	RE
Rovi Responds to Press Speculation Regarding Contract Development Business Deal	Mar. 07	MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024	Feb. 27
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 25	CI
US FDA finds control lapses at Moderna manufacturing plant	Dec. 15	RE
Italy, Spain stocks hit peaks after over 20% rally in 2023	Nov. 30	RE
Laboratorios Farmaceuticos Rovi S A : First nine months 2023 results press release	Nov. 10	PU
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 08	CI
Laboratorios Farmaceuticos Rovi S A : ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®	23-07-28	PU
Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2023 Earnings Call, Jul 26, 2023	23-07-26
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-26	CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.	23-07-26	CI
Laboratorios Farmaceuticos Rovi S A : First half 2023 results press release	23-07-26	PU
Ex-dividend day for final dividend	23-07-02	FA
Global markets live: Macy's, Salesforce, Dollar General, Nordstrom, Exxon...	23-06-01
Laboratorios Farmaceuticos Rovi Denies Receiving Unlawful Public Grants	23-05-31	MT
Laboratorios Farmaceuticos Rovi S A : First quarter 2023 results press release	23-05-10	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Laboratorios Farmaceuticos Rovi, S.A.

Equities

ROVI

ES0157261019

Summary

Filters